Skip to main content
. 2015 Jul 20;6(20):17895–17910. doi: 10.18632/oncotarget.4963

Figure 1. Point mutations in MTOR are clustered in various regulatory domains in ccRCCC and are associated with poor prognosis.

Figure 1

a. Analysis of ccRCC cases from the COSMIC and cBIO databases show that mTOR mutations are present in about 6% cases of cases. Clusters of mTOR mutations are represented in the various domains of mTOR. b. Sites of mTOR mutations reported in RCC are indicated as grey spheres on the structure of mTORΔN (PDB ID code: 4JSN). The catalytic site is represented with pink spheres, and the domains are colored as indicated previously. KD-N and KD-C represent the N and C terminal lobes of the kinase domain. Inset: Structure of the TRD (Tetratricopeptide repeat domains)1/2 regions (1385-1666) of the FAT domain with the sites of mutations characterized in this study represented as spheres and coloured by atom type (C, grey; O, red; N, blue; S, orange). These mutations were clustered in the kinase and FAT domains of mTOR. c. Survival of RCC patients as a function of MTOR mutation.